These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15330798)

  • 1. Testing for HER2 in breast cancer.
    Lewis F; Jackson P; Lane S; Coast G; Hanby AM
    Histopathology; 2004 Sep; 45(3):207-17. PubMed ID: 15330798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current perspectives on HER2 testing: a review of national testing guidelines.
    Bilous M; Dowsett M; Hanna W; Isola J; Lebeau A; Moreno A; Penault-Llorca F; Rüschoff J; Tomasic G; van de Vijver M
    Mod Pathol; 2003 Feb; 16(2):173-82. PubMed ID: 12591971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.
    Hicks DG; Tubbs RR
    Hum Pathol; 2005 Mar; 36(3):250-61. PubMed ID: 15791569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
    Press MF; Sauter G; Bernstein L; Villalobos IE; Mirlacher M; Zhou JY; Wardeh R; Li YT; Guzman R; Ma Y; Sullivan-Halley J; Santiago A; Park JM; Riva A; Slamon DJ
    Clin Cancer Res; 2005 Sep; 11(18):6598-607. PubMed ID: 16166438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier.
    Balluff B; Elsner M; Kowarsch A; Rauser S; Meding S; Schuhmacher C; Feith M; Herrmann K; Röcken C; Schmid RM; Höfler H; Walch A; Ebert MP
    J Proteome Res; 2010 Dec; 9(12):6317-22. PubMed ID: 21058730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
    Barberis M; Pellegrini C; Cannone M; Arizzi C; Coggi G; Bosari S
    Am J Clin Pathol; 2008 Apr; 129(4):563-70. PubMed ID: 18343783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescent in situ hybridization as a primary test for HER2 status in breast cancer: controversies.
    Arena V; Pennacchia I; Monego G; Carbone A; Capelli A
    J Clin Oncol; 2010 Feb; 28(5):e83-4; author reply e85-8. PubMed ID: 20065180
    [No Abstract]   [Full Text] [Related]  

  • 10. External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme.
    Bartlett JM; Ibrahim M; Jasani B; Morgan JM; Ellis I; Kay E; Connolly Y; Campbell F; O'Grady A; Barnett S; Miller K
    Am J Clin Pathol; 2009 Jan; 131(1):106-11. PubMed ID: 19095573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M; Morey A; Armes J; Cummings M; Francis G
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice.
    Farshid G; Armes JE; Bell R; Cummings M; Fox S; Francis G; Haswell M; Morey A; McCue G; Raymond W; Robbins P; Bilous M
    Diagn Mol Pathol; 2010 Dec; 19(4):187-93. PubMed ID: 21052003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service.
    Faratian D; Graham A; Rae F; Thomas J
    Histopathology; 2009 Mar; 54(4):428-32. PubMed ID: 19309394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
    Graham AD; Faratian D; Rae F; Thomas JS
    Histopathology; 2008 Jun; 52(7):847-55. PubMed ID: 18494613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
    Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
    Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17.
    Torrisi R; Rotmensz N; Bagnardi V; Viale G; Curto BD; Dell'orto P; Veronesi P; Luini A; D'Alessandro C; Cardillo A; Goldhirsch A; Colleoni M
    Eur J Cancer; 2007 Nov; 43(16):2339-44. PubMed ID: 17855075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies.
    Tapia C; Schraml P; Simon R; Al-Kuraya KS; Maurer R; Mirlacher M; Novotny H; Spichtin H; Mihatsch MJ; Sauter G
    Int J Oncol; 2004 Dec; 25(6):1551-7. PubMed ID: 15547690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 assessment by silver in situ hybridization: where are we now?
    Sanguedolce F; Bufo P
    Expert Rev Mol Diagn; 2015 Mar; 15(3):385-98. PubMed ID: 25578771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic variables.
    Rasmussen BB; Andersson M; Christensen IJ; Møller S
    Acta Oncol; 2008; 47(4):784-8. PubMed ID: 18465349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.